A post-transplantation lymphoproliferative disease (PTLD) of recipient origin was identified in one of 376 consecutive cases of allogeneic bone marrow transplantation (BMT). This occurred in a 36-year-old woman who received an allogeneic BMT for acute myeloid leukaemia in relapse. At 15 months after BMT, recipient haematopietic and leukaemic cells were found in the bone marrow, which disappeared on withdrawal of immunosuppression. However, severe graft-versus-host disease (GVHD) necessitated the continuation of immunosuppression, leading to the occurrence of PTLD in the liver and lung 12 months afterwards. Fluorescence in situ hybridisation showed that the neoplastic cells were of recipient origin. Although the PTLD also responded completely to withdrawal of immunosuppression, the patient finally died from the complications of GVHD. This case of late onset PTLD post-BMT showed features similar to those in solid organ transplantation, in that the tumour was of recipient origin and responded well to the withdrawal of immunosuppression. Of further interest is that recipient lymphoid regeneration had accompanied autologous haematopoietic regeneration and become a target for subsequent neoplastic transformation. Bone Marrow Transplantation (2001) 28, 417-419. Keywords: post-transplant lymphoproliferative disease; recipient origin Post-transplantation lymphoproliferative disease (PTLD) is a rare complication after bone marrow transplantation (BMT). Based on registry data, the incidence after BMT is around 1%. PTLD usually occurs within 6 months of BMT and runs a fulminant course. Most studied cases are of donor origin. We report a unique case of late-onset PTLD of recipient origin. 
Materials and methods

Patients
From 1989 to 2000, 376 adult allogeneic BMT were performed in Queen Mary Hospital. The donors were siblings (n = 324), parents (n = 3) or unrelated (n = 49). There were two cases of early-onset, fatal disseminated PTLD, both in patients receiving a one-HLA antigen mismatched allogeneic BMT. One patient developed a late onset PTLD, who is the subject of this report.
Molecular cytogenetic analyses
Cytogenetic (CG) analyses were performed on direct 24-h unstimulated culture of cell suspensions from marrow aspirates. Metaphases were Giemsa-banded and karyotyped according to ISCN (1995) . Reverse transcription polymerase chain reaction (RT-PCR) for AML1/ETO was performed as previously described, 1 with a sensitivity of 10
. Fluorescence in situ hybridisation (FISH) was performed on microdissected paraffin-fixed liver biopsy sections and cytogenetic preparation of marrow metaphases, with chromosome X and Y centromeric probes (Vysis, Downers Grove, IL, USA). 2 For microdissection, the tumour cells were carefully removed from surrounding liver cells under microscopic guidance, after correlation with morphology on haematoxylin-eosin-stained sections. After FISH, the tumour cells were then restained for morphological confirmation. In situ hybridisation for Epstein-Barr virus expressed RNA (EBER) was performed as previously described. 
Results
A 36-year-old woman with AML/t(8;21)(q22;q22) in untreated first relapse underwent allogeneic BMT from her HLA-identical brother. Busulphan (7 mg/kg), cyclophosphamide (50 mg/kg) and total body irradiation 12 Gy was used as conditioning, and cyclosporine and methotrexate were given for graft-versus-host disease (GVHD) prophylaxis. She engrafted with grade II acute GVHD and exten-sive chronic GVHD requiring treatment with azathioprine, corticosteroids and cyclosporine. Cytogenetic studies showed complete engraftment with donor cells (46,XY). At 15 months post-BMT, although the marrow was morphologically normal, cytogenetic analysis showed the presence of recipient cells (46,XY [12] /46,XX,t(8;21)(q22;q22) [3] / 92,XXXX [1] ), consistent with autologous regeneration and cytogenetic relapse. Immunosuppression was stopped, resulting in severe GVHD but cytogenetic remission (46,XY[15]). RT-PCR was also negative for AML1/ETO. Azathioprine, corticosteroids and cyclosporine were resumed. At 30 months post-BMT, she developed fever and liver function derangement. A computerised tomogram (CT) scan showed numerous hypodense lesions in the liver and lungs (Figure 1a) . A liver biopsy showed extensive infiltration by monomorphic sheets of CD20 + centroblasts, which were strongly positive for EBER. On FISH analysis, the microdissected tumour cells showed two X chromosome hybridisation signals without any Y chromosome signal, confirming the host origin of the lymphoma cells (Figure 1c,d) . However, the marrow remained in remission and donor chimerism was maintained, as shown by conventional cytogenetics (46,XY [8] ) and FISH analysis (Figure 1e ), although at this time RT-PCR had become positive for AML1/ETO. All immunosuppression was stopped again, resulting in a rapid resolution of the lesions and symptoms in 2 weeks (Figure 1b) . In spite of the gradual re-introduction of steroids and azathioprine, the patient died 6 months later from the complications of chronic GVHD. 
Discussion
PTLD after allogeneic BMT is a rare disease, with a registry incidence of around 1%. 4 Identified risk factors include mismatched BMT, severe GHVD and the use of antithymoctye globulin, T cell depletion and total body irradiation. [4] [5] [6] The disease incidence peaks at 3 months, and falls sharply after 1 year, 4 after the reconstitution of anti-EBV T cell immunocompetence. 7 PTLD is invariably of donor origin, caused by the proliferation of donor-derived EBV-infected B cells before the recovery of anti-EBV T cell immunity. This is not unexpected, as the BMT conditioning regimen ablates recipient haemato-lymphopoiesis, so that lymphoproliferative diseases should not arise from recipient cells. Post-BMT PTLD is mostly disseminated with a poor survival, although the prognosis may be better with localized disease and treatment with donor lymphocyte infusion. 8, 9 Our present case of PTLD of recipient origin after allogeneic BMT is therefore interesting in several aspects. The patient had initial autologous marrow regeneration and leukaemic relapse, followed by PTLD. This implied that the conditioning regimen had been neither myeloablative nor lymphoablative. However, both the leukaemic relapse and PTLD responded to the withdrawal of immunosuppression, implying that donor-derived immunocompetent cells, rather than the conditioning regimen, were instrumental in maintaining disease control and full donor haematolymphoid chimaerism.
Moreover, the clinicopathological features and response to treatment of our case were similar in many aspects to PTLD complicating solid organ transplantation, where the neoplastic cells are usually of recipient origin. First, there was a long latency of 30 months, comparable to the median of 7 to 80 months in reported series of PTLD after solid organ transplantation. [10] [11] [12] Second, the disease was localised rather than disseminated at presentation. Finally, there was a dramatic response to withdrawal of immunosuppression. Thus, in post-BMT PTLD, the determination of the donor vs recipient origin of the neoplastic cells might have pathogenetic and therapeutic implications.
Lastly, although the PTLD responded well to withdrawal of immunosuppression, the patient finally died from GVHD. Experimental approaches including the use of specific anti-EBV adoptive immuno-transfer, which provides therapeutic efficacy but without aggravating GVHD, may be required to improve the prognosis in these patients. 13 
